Dechra Pharmaceuticals delivered FY15 revenue growth of 10% CER to £203.5m and EPS growth of 16.9% from 36.3p to 39.9p, with strong sales performances in its Companion Animal Products (CAP) segment, up 15%, and North American sales up 60% (CER). The global strategy centres on sustained organic and acquisitive growth. Our financial forecasts are under review subject to completing the conditional offer for Genera dd, based in Croatia, anticipated in November.
